For men who undergo a radical prostatectomy for the treatment of prostate cancer, post-surgery radiation therapy can play a vital role in reducing the risk of recurrence. Despite its benefits, many ...

Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

Men given two larger doses of radiation had about the same side effects as others treated with the standard five-dose course, ...

Researchers found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, is as safe as conventional treatment, with similar side effects and a ...

A groundbreaking new study suggests that prostate cancer treatment may soon become faster, simpler, and less disruptive for ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

A retrospective study finds higher long-term overall survival after radical prostatectomy (with or without salvage treatment) for clinically node-positive prostate cancer. Radical prostatectomy (RP) ...

At the recent American Urological Association (AUA) annual meeting, focal therapies for localized prostate cancer took center stage, moving from a niche option to a recognized alternative to surgery ...

SpaceOAR Hydrogel reduces radiation exposure to the rectum, minimizing bowel-related side effects in prostate cancer patients undergoing radiation therapy. A study showed a 25% reduction in bowel ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

Advances in radiotherapy are rapidly transforming how prostate cancer is treated, offering patients more precise, less invasive options that can fit more easily around everyday life ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.